News

benzinga_article
2025.12.01 19:23
Citius Oncology shares are trading higher after the company announced the commercial launch of LYMPHIR, FDA-Approved IL-2 receptor-directed fusion protein, for the treatment of adult patients with r/r Stage I–III cutaneous T-cell lymphoma after at least one prior systemic therapy.
Source: benzinga_article The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
© 2025 Longbridge｜Disclaimer